Company / Interest Expense
Travere Therapeutics, Inc. Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$11.3M
FY2023
5-year range
$11.0M / $18.8M
FY2019-FY2023
Trend
+2.7%
vs FY2022
Sector context
#27 of 44
Health Care
What the data says
At $11M, Travere Therapeutics, Inc.'s interest expense ranks #18 of 44 in the Health Care sector. Interest Expense has fluctuated over the past 8 years, ranging from $4M in FY2019 to $19M in FY2021.
Based on SEC 10-K filings.
$11M in FY2023 with a 5-year CAGR of +19.0%.
Improved from $19M to $11M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +4.8%
- 5-Year CAGR
- +19.0%
- 10-Year CAGR
- -
Sector benchmark
#18 of 44 in Health CareTop 39% of 44This company $11.3M Sector average $291.0M
▼
-96.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.0%, indicating consistent growth.
- In FY2023, interest expense increased 2.7% year-over-year.
- Ranks #27 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $11.3M | +2.7% |
| FY2022 | $11.0M | -41.5% |
| FY2021 | $18.8M | +91.6% |
| FY2020 | $9.8M | +121.8% |
| FY2019 | $4.4M | -6.6% |
| FY2018 | $4.7M | -38.5% |
| FY2017 | $7.7M | +4.1% |
| FY2016 | $7.4M | -3.9% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026